Allegro Ophthalmics has added ALG-1007, a new anti-integrin drug candidate for the treatment of dry eye disease, to its portfolio, the company announced in a press release.
The topical agent is under evaluation in a phase 2 study outside of the U.S. and is the company’s first exploratory drug not in the retina space.
“While we remain focused on and committed to our retina portfolio, we at Allegro are continuously exploring new ways to apply our anti-integrin assets to help improve patients’ vision,” Vicken Karageozian, MD, president and CEO of (Read more...)
Uncategorized